Carol Schafer
Director/Board Member at REPARE THERAPEUTICS INC.
Net worth: 1 M $ as of 30/04/2024
Carol Schafer active positions
Companies | Position | Start | End |
---|---|---|---|
REPARE THERAPEUTICS INC. | Director/Board Member | 01/03/2019 | - |
Independent Dir/Board Member | 01/03/2019 | - | |
INSMED INCORPORATED | Director/Board Member | 01/04/2020 | - |
Independent Dir/Board Member | 01/04/2020 | - | |
KURA ONCOLOGY, INC. | Director/Board Member | 03/06/2021 | - |
Independent Dir/Board Member | 03/06/2021 | - | |
IMMUNOME, INC. | Director/Board Member | 02/01/2024 | - |
Independent Dir/Board Member | 02/01/2024 | - | |
Hyphen Advisors LLC | Chief Executive Officer | 01/01/2018 | - |
Onegoal New York
Onegoal New York Miscellaneous Commercial ServicesCommercial Services Onegoal New York operates a social services organization. The private company is based in New York. | Director/Board Member | 01/03/2019 | - |
Career history of Carol Schafer
Former positions of Carol Schafer
Companies | Position | Start | End |
---|---|---|---|
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Director/Board Member | 18/12/2018 | 28/09/2022 |
Independent Dir/Board Member | 18/12/2018 | 28/09/2022 | |
FIVE PRIME THERAPEUTICS, INC. | Director/Board Member | 15/05/2019 | 16/04/2021 |
Independent Dir/Board Member | 15/05/2019 | 16/04/2021 | |
Wells Fargo Securities LLC
Wells Fargo Securities LLC Investment ManagersFinance Wells Fargo Securities LLC (WFS) is the broker/dealer subsidiary of EVEREN Capital Corp., ultimately owned by Wells Fargo & Co. (NYSE: WFC). Headquartered in New York, WFS delivers a comprehensive suite of banking, capital markets and advisory solutions, such as a full complement of sales, trading and research capabilities, to corporate, government and institutional clients. | Corporate Officer/Principal | 01/04/2007 | 01/09/2018 |
░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░ ░░░░░░ ░ ░░░░ ░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Training of Carol Schafer
Boston College | Undergraduate Degree |
The Leonard N Stern School of Business | Masters Business Admin |
Statistics
International
United States | 13 |
Canada | 2 |
Operational
Director/Board Member | 7 |
Independent Dir/Board Member | 6 |
Corporate Officer/Principal | 2 |
Sectoral
Health Technology | 8 |
Finance | 3 |
Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 5 |
---|---|
LEXICON PHARMACEUTICALS, INC. | Health Technology |
INSMED INCORPORATED | Health Technology |
IMMUNOME, INC. | Health Technology |
KURA ONCOLOGY, INC. | Health Technology |
REPARE THERAPEUTICS INC. | Health Technology |
Private companies | 6 |
---|---|
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Health Technology |
Five Prime Therapeutics, Inc.
Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
J.P. Morgan & Co., Inc. (Old) | Finance |
Wells Fargo Securities LLC
Wells Fargo Securities LLC Investment ManagersFinance Wells Fargo Securities LLC (WFS) is the broker/dealer subsidiary of EVEREN Capital Corp., ultimately owned by Wells Fargo & Co. (NYSE: WFC). Headquartered in New York, WFS delivers a comprehensive suite of banking, capital markets and advisory solutions, such as a full complement of sales, trading and research capabilities, to corporate, government and institutional clients. | Finance |
Onegoal New York
Onegoal New York Miscellaneous Commercial ServicesCommercial Services Onegoal New York operates a social services organization. The private company is based in New York. | Commercial Services |
Hyphen Advisors LLC |
- Stock Market
- Insiders
- Carol Schafer
- Experience